Difference between revisions of "Blinatumomab (Blincyto)"
Jump to navigation
Jump to search
m |
|||
| Line 18: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *12/3/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm425597.htm Granted FDA accelerated approval] for the treatment of [[Biomarkers#BCR-ABL1|Philadelphia chromosome]]-[[Biomarkers#Normal_expression|negative]] relapsed or refractory [[B-cell_acute_lymphoblastic_leukemia | B-cell precursor acute lymphoblastic leukemia]] (R/R ALL). ''(Based on MT103-211 | + | *12/3/2014: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm425597.htm Granted FDA accelerated approval] for the treatment of [[Biomarkers#BCR-ABL1|Philadelphia chromosome]]-[[Biomarkers#Normal_expression|negative]] relapsed or refractory [[B-cell_acute_lymphoblastic_leukemia | B-cell precursor acute lymphoblastic leukemia]] (R/R ALL). ''(Based on MT103-211)'' |
| − | *7/11/2017: Granted FDA regular approval for the treatment of relapsed or refractory [[B-cell_acute_lymphoblastic_leukemia|B-cell precursor acute lymphoblastic leukemia (ALL)]] in adults and children. ''(Based on TOWER)'' | + | *7/11/2017: Granted FDA regular approval for the treatment of relapsed or refractory [[B-cell_acute_lymphoblastic_leukemia|B-cell precursor acute lymphoblastic leukemia (ALL)]] in adults and children. ''(Based on TOWER, MT103-205, and ALCANTARA)'' |
*3/29/2018: Granted FDA accelerated approval for the treatment of adult and pediatric patients with [[B-cell_acute_lymphoblastic_leukemia|B-cell precursor acute lymphoblastic leukemia (ALL)]] in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ''(Based on BLAST)'' | *3/29/2018: Granted FDA accelerated approval for the treatment of adult and pediatric patients with [[B-cell_acute_lymphoblastic_leukemia|B-cell precursor acute lymphoblastic leukemia (ALL)]] in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ''(Based on BLAST)'' | ||
Revision as of 17:51, 10 May 2021
General information
Class/mechanism: Bi-specific T-cell engager (BiTE) antibody that targets CD19 (expressed on B cells) and CD3 (expressed on T cells).[1][2][3]
Route: IV
Extravasation: no information
- Use of Blinatumomab (Blincyto) requires participation in the Blincyto Risk Evaluation and Mitigation Strategy (REMS) program.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Patient information may be found in the Blinatumomab (Blincyto) package insert.[1]
- Blinatumomab (Blincyto) patient drug information (Chemocare)[4]
- Blinatumomab (Blincyto) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 12/3/2014: Granted FDA accelerated approval for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL). (Based on MT103-211)
- 7/11/2017: Granted FDA regular approval for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children. (Based on TOWER, MT103-205, and ALCANTARA)
- 3/29/2018: Granted FDA accelerated approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. (Based on BLAST)
Also known as
- Code names: AMG 103, MEDI538, MT103
- Brand name: Blincyto